Stock listing

NASDAQ:VIR Vir Biotechnology, Inc. Stock

Home listing (NASDAQ) of Vir Biotechnology, Inc.

Follow Vir Biotechnology, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VIR

$8.39 USD -0.76 (-8.3%)

Close on Nov 20, 2026

Past year +50.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.34 – $8.92 USDNov 20, 2026
Volume
3.09M sharesNov 20, 2026
Market cap
$1.44B USDAt the close on Nov 20, 2026 · price × 171.3M shares outstanding
52-week range
$5.45 – $14.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$26.35M USDMedian day 1.85M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Vir Biotechnology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VIR · Home$8.39 USD-0.76 (-8.3%)3,088,951$8.807$8.915$8.34$9.15Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VIR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.39-0.76-8.3%$8.807$8.915$8.343,088,951
$9.15-0.10-1.1%$9.17$9.361$9.0152,153,818
$9.25-0.33-3.4%$9.53$9.75$9.033,480,042
$9.58-0.38-3.8%$9.85$10.03$9.576,777,369
$9.96-2.16-17.8%$10.46$10.70$9.7116,658,905
$12.12-1.01-7.7%$12.90$12.96$12.021,945,044
$13.13-0.02-0.2%$13.15$13.43$12.941,291,852
$13.15-0.495-3.6%$13.66$13.74$13.111,299,670
$13.65+1.435+11.8%$13.18$14.38$13.117,120,581
$12.21+1.19+10.8%$11.30$12.45$11.301,886,950
$11.02-0.75-6.4%$11.92$12.16$10.982,922,141
$11.77+0.55+4.9%$11.68$11.81$11.172,425,081
$11.22+0.22+2.0%$11.10$11.38$11.101,553,082
$11.00-0.30-2.7%$11.36$11.55$11.001,377,376
$11.30-0.45-3.8%$11.63$11.84$11.181,267,213
$11.75-0.18-1.5%$11.75$12.19$11.551,421,661
$11.93+0.36+3.1%$11.43$11.95$11.201,557,240
$11.57+0.53+4.8%$11.00$11.63$10.861,972,473
$11.04+0.47+4.4%$10.64$11.09$10.601,587,106
$10.57+0.14+1.3%$10.36$10.59$10.031,693,540
$10.43-0.14-1.3%$10.51$10.75$10.18986,582
$10.57-0.17-1.6%$10.80$11.02$10.551,136,654
$10.74+0.53+5.2%$10.19$10.87$10.141,329,595
$10.21+0.25+2.5%$10.07$10.30$9.961,309,172
$9.96-0.51-4.9%$10.49$10.49$9.911,735,300
$10.47+0.06+0.6%$10.38$10.67$10.201,417,900
$10.41-0.20-1.9%$10.95$11.11$10.342,764,900
$10.61-0.69-6.1%$11.21$11.25$10.601,783,600
$11.30-0.40-3.4%$11.63$11.82$11.211,086,200
$11.70+0.58+5.2%$11.11$12.00$10.971,965,100
$11.12-0.40-3.5%$11.52$11.56$10.733,071,100
$11.52-0.08-0.7%$11.32$11.77$11.323,561,900
$11.60-0.18-1.5%$11.90$11.90$11.262,586,700
$11.78+0.61+5.5%$11.17$11.87$10.923,147,200
$11.17-0.12-1.1%$11.55$11.73$10.952,180,600
$11.29+0.11+1.0%$10.86$11.61$10.862,575,800
$11.18+0.53+5.0%$10.70$11.26$10.541,737,500
$10.65+0.14+1.3%$10.49$10.85$10.341,573,700
$10.51-0.15-1.4%$10.56$10.69$10.331,369,900
$10.66-0.06-0.6%$10.82$10.82$10.481,126,000
$10.72-0.37-3.3%$11.02$11.16$10.352,085,200
$11.09-0.41-3.6%$11.44$11.53$10.851,684,800
$11.50+0.62+5.7%$10.99$11.72$10.891,852,000
$10.88+0.28+2.6%$10.77$10.95$10.661,454,900
$10.60-0.32-2.9%$10.92$11.00$10.447,017,200
$10.92+0.40+3.8%$10.87$11.21$10.681,791,300
$10.52+0.08+0.8%$10.54$10.67$10.392,091,100
$10.44-0.325-3.0%$10.71$10.73$10.232,282,200
$10.77+0.145+1.4%$10.73$10.94$10.641,841,500
$10.62+0.04+0.4%$10.79$10.95$10.382,078,000
$10.58-0.23-2.1%$10.57$10.79$10.451,855,300
$10.81-0.37-3.3%$11.04$11.38$10.741,945,600
$11.18-0.205-1.8%$11.22$11.28$10.991,613,900
$11.39-0.065-0.6%$11.31$11.65$11.181,151,300
$11.45-0.05-0.4%$11.54$11.62$11.072,565,400
$11.50-0.13-1.1%$11.63$11.94$11.353,019,800
$11.63+0.69+6.3%$10.80$11.74$10.802,778,100
$10.94+0.11+1.0%$10.77$11.17$10.653,046,500
$10.83-0.48-4.2%$11.16$11.46$10.801,835,200
$11.31+0.23+2.1%$11.00$11.46$10.841,737,300
$11.08+0.37+3.5%$10.60$11.12$10.302,248,500
$10.71+0.80+8.1%$10.03$11.28$9.972,961,369
$9.91+0.13+1.3%$9.74$9.975$9.4351,739,718
$9.78+0.57+6.2%$9.31$9.86$9.3051,756,400
$9.21-0.56-5.7%$9.61$9.71$9.0251,060,400
Ticker
NASDAQ:VIR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Vir Biotechnology, Inc. news

Vir Biotechnology, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
37 in the last 12 months · 246 in all · newest Nov 13, 2026 · oldest 2019
Calls
14 calls with a replay · 14 with a transcript · latest Nov 4, 2026
Decks
32 decks · latest Nov 9, 2026

Where Vir Biotechnology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VIR · Home listing · This pageNASDAQUnited StatesUSD
BMV:VIRBMVMexicoMXN
BIVA:VIRBIVAMexicoMXN
BX Swiss:VIRBX SwissSwitzerlandCHF
BOATS:VIRBOATSUnited StatesUSD

Valuation

EV/sales 3.5× against a median of 52.7×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.07B USD
P/E
Loss
EV/sales
3.5×
EV/EBITDA
Negative EBITDA
Price/book
1.6×
Gross margin
97.2%
Operating margin
−69.8%
Net margin
−61.0%
Debt to equity
0.1×
Beta vs S&P 500
1.82

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
Alvotech · NASDAQ:ALVOUS$1.47BUS$2.78Bn/a5.7×31.4×n/a−36.5%n/a0.90
ABL Bio, Inc. · KRX:298380US$1.47BUS$1.34Bn/a52.7×n/a11.5×−229.4%0.0×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.5×n/a2.4×−593.9%0.2×n/a
PELL Bio-Med Technology Co Ltd · TWSE:6949US$1.46BUS$1.40Bn/a1,591×n/a18.7×n/a0.1×n/a
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Voronoi, Inc. · KRX:310210US$1.44BUS$1.39Bn/an/an/a27.9×n/a0.5×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
LigaChem Biosciences Inc. · KRX:141080US$1.42BUS$1.14Bn/a15.5×n/a4.8×−180.9%0.0×n/a
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Median of the othersUS$1.44BUS$1.37B52.7×31.4×2.9×−180.9%0.0×1.09

Forecasts

5 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
23.13 USD · Analysts' mean
EPS, year to Dec 2026
-1.01 · 8 analysts
Revenue, year to Dec 2026
327.2M · 8 analysts

Team and board

Officers

OfficerRole
Marianne De BackerPRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR
Aziz SawafEXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICer
Vanina de VerneuilExecutive Vice President General Counsel and Corporate Secretary
Carolyn WangSENIOR VICE PRESIDENT CORPORATE COMMUNICATIONS
InvestorsNeera RavindranMDHead of Investor Relations & Strategic
Kiki PatelPharmDHead of Investor Relations
David LiuEXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER
Jeff CalcagnoExecutive Vice President and Chief Business Officer
Jennifer Eileen TowneExecutive Vice President and Chief Scientific Officer
Maninder HoraEXECUTIVE VICE PRESIDENT AND CHIEF TECHNICAL OPERATIONS OFFICER
Toby MedarisEXECUTIVE VICE PRESIDENT AND CHIEF HUMAN RESOURCES OFFICER
Brent SabatiniInterim Principal Financial Officer

Board

DirectorRole
Jeffrey S. HatfieldChair of the Board
Elliott SigalDirector
Janet NapolitanoDirector
Marianne De BackerPRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR
Norbert BischofbergerDirector
Ramy FaridDirector
Robert MoreDirector
Suzanne L. TopalianDirector
Timothy CoughlinDirector

Events

Calls

CallWhenStatus
Vir Biotechnology (NASDAQ:VIR) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q2 2026 Earnings CallWed, Aug 05, 2026 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q1 2026 Earnings CallWed, May 06, 2026 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q4 2025 Earnings CallMon, Feb 23, 2026 · 5:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q3 2025 Earnings CallWed, Nov 05, 2025 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q2 2025 Earnings CallWed, Aug 06, 2025 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q1 2025 Earnings CallWed, May 07, 2025 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q4 2024 Earnings CallWed, Feb 26, 2025 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q3 2024 Earnings CallThu, Oct 31, 2024 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
All 14 calls
CallWhenStatus
Vir Biotechnology (NASDAQ:VIR) Q1 2024 Earnings CallThu, May 02, 2024 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q4 2023 Earnings CallThu, Feb 22, 2024 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q3 2023 Earnings CallThu, Nov 02, 2023 · 4:30 PM ETReplay
Vir Biotechnology (NASDAQ:VIR) Q2 2023 Earnings CallThu, Aug 03, 2023 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−6.4%
Q2 2026Aug 5, 2026 · After close−3.8%
Q1 2026May 6, 2026 · After close−9.9%
Q4 2025Feb 23, 2026+25.5%
Q3 2025Nov 5, 2025 · After close−5.2%
Q2 2025Aug 6, 2025 · After close−14.4%
Q1 2025May 7, 2025 · After close−3.6%
Q4 2024Feb 20, 2025 · After close−2.4%
Q3 2024Oct 31, 2024 · After close+23.6%
Q2 2024Aug 1, 2024 · After close−5.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+13.2%
Q4 2023Feb 22, 2024 · After close+11.9%
Q3 2023Nov 2, 2023 · After close+7.0%
Q2 2023Aug 3, 2023 · After close−2.5%
Q1 2023May 4, 2023 · After close−3.9%
Q4 2022Feb 23, 2023 · After close−10.9%
Q3 2022Nov 3, 2022 · After close+17.7%
Q2 2022Aug 9, 2022 · After close+6.3%
Q1 2022May 5, 2022 · After close+3.5%
Q4 2021Feb 24, 2022 · After close−1.4%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical23 slidesNov 9, 2026
Q3 2026 Earnings PresentationEarnings61 slidesNov 4, 2026
Q2 2026 Earnings PresentationEarnings62 slidesAug 5, 2026
Technical Presentation (May 2026)Technical10 slidesMay 6, 2026
Q1 2026 Earnings PresentationEarnings61 slidesMay 6, 2026
FY2025 Earnings PresentationEarnings35 slidesFeb 23, 2026
Q4 2025 Earnings PresentationEarnings56 slidesFeb 23, 2026
J.P. Morgan 2026 Healthcare ConferenceConference26 slidesJan 12, 2026
Q3 2025 Earnings PresentationEarnings45 slidesNov 5, 2025
Investor Presentation (November 2025)Investor deck47 slidesNovember 2025
All 32 decks
DeckKindSlidesDate
Q2 2025 Earnings PresentationEarnings45 slidesAug 6, 2025
Q4 2024 Earnings PresentationEarnings45 slidesFeb 26, 2025
43rd Annual J.P. Morgan Healthcare Conference 2025Conference18 slidesJan 14, 2025
Investor Presentation (January 2025)Investor deck41 slidesJan 8, 2025
Hepatitis Investor Event at AASLD 2024Conference49 slidesNov 19, 2024
Q3 2024 Earnings PresentationEarnings50 slidesOct 31, 2024
Q2 2024 Earnings PresentationEarnings39 slidesAug 1, 2024
Goldman Sachs 45th Annual Global Healthcare Conference 2024Conference5 slidesJun 12, 2024
Investor Presentation (June 2024)Investor deck36 slidesJun 8, 2024
European Association for the Study of the Liver (EASL) Congress 2024Conference15 slidesJun 8, 2024
EASL Congress 2024 Investor Conference CallConference27 slidesJun 5, 2024
Shareholder Meeting (May 2024)Shareholder meeting12 slidesMay 14, 2024
Q1 2024 Earnings PresentationEarnings30 slidesMay 2, 2024
Q4 2023 Earnings PresentationEarnings27 slidesFeb 22, 2024
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference25 slidesJan 10, 2024
AASLD Late Breaking Data Update Call 2023Conference32 slidesNov 13, 2023
Q3 2023 Earnings PresentationEarnings12 slidesNov 2, 2023
Corporate Update (February 2022)Corporate update20 slidesFeb 24, 2022
EASL ILC 2021 Hepatitis B Data CallConference20 slidesJun 28, 2021
Investor Presentation (May 2021)Investor deck19 slidesMay 27, 2021
20th Annual Needham Healthcare Conference 2021Conference19 slidesApr 13, 2021
H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)Conference28 slidesSep 16, 2020

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: US$150M · US$10 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Evercore ISI (co-lead), Raymond James
Nov 13, 2026
Strategic investment of equity
Announced: US$25M
Buyers: Gilead ($25 million equity investment at a 30% premium)
Oct 14, 2026
Strategic investment of shares
Closed: US$75M raised · US$10.36 a share
Buyers: Astellas ($75 million equity investment at a price of $10.36 per share)
Apr 16, 2026
Public offering of common stock
Terms changed: US$150M · US$8.5 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Barclays (co-lead)
Feb 26, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$20.00 a share on Oct 10, 2019.

Price
US$20.00 a share
Shares offered
7,142,858 shares of common stock
Offering size
US$142.9 million
Underwriters' option
Up to 1,071,428 more shares
Underwriters
Goldman Sachs & Co. LLC, J.P. Morgan, Cowen, Barclays · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJun 27, 2019
Filed publiclySep 3, 2019
Amended onceSep 30, 2019
Shares registered with an exchangeOct 9, 2019
Declared effective by the SECOct 10, 2019
Final prospectus, with the priceOct 11, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue68.6M74.2M86.2M1.62B1.10B76.4M8.09M10.7M2.71M
Cost of revenue26.0K845.0K2.77M146.3M65.9M00100.2M62.5M
Gross profit56.9M58.8M64.0M1.45B1.02B76.4M711.0K-99.4M-62.4M
Research and development456.0M506.5M579.7M474.6M448.0M302.4M148.5M100.2M62.5M
Selling, general and administrative92.1M119.0M174.4M161.8M160.8M70.9M37.6M29.1M21.7M
Operating income-479.3M-587.2M-684.3M833.1M420.8M-297.0M-178.0M-118.7M-81.5M
Depreciation and amortization11.7M14.6M19.5M6.78M5.28M4.40M3.29M1.62M255.0K
EBITDA-467.6M-572.6M-664.9M839.9M426.0M-292.6M-174.7M-117.1M-81.2M
Interest expense183.1M272.9M3.81M7.97M00
Income before tax-437.8M-523.1M-628.2M754.3M549.8M-298.6M-174.5M-116.4M-80.8M
Income tax217.0K-1.15M-13.1M238.4M21.2M54.0K154.0K-480.0K-10.9M
Net income-438.0M-522.0M-615.1M515.8M528.6M-298.7M-174.7M-115.9M-69.9M
Earnings per share, basic-3.16-3.83-4.593.894.07-2.51-5.76-15.12-32.45
Earnings per share, diluted-3.16-3.83-4.593.833.96-2.51-5.76-15.12-32.45

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents232.2M222.9M241.6M848.6M347.8M436.6M109.3M47.6M187.9M
Short-term investments228.8M678.1M1.27B1.52B217.2M300.3M274.1M50.8M0
Receivables3.60M5.10M11.6M0773.1M0
Inventory8.59M00
Current assets514.1M1.04B1.59B2.52B1.56B772.4M403.0M117.8M192.3M
Property, plant and equipment55.6M63.2M96.0M105.6M42.8M17.9M16.3M12.3M5.14M
Goodwill16.9M16.9M16.9M16.9M16.9M16.9M16.9M16.9M16.9M
Total assets1.00B1.40B1.92B2.80B1.95B918.8M512.1M191.6M251.6M
Accounts payable9.80M5.08M6.33M6.42M6.52M5.08M5.88M6.47M4.90M
Current liabilities92.8M119.7M175.4M511.0M341.2M99.1M59.2M39.9M12.4M
Long-term debt00
Total debt186.9M97.9M124.5M128.0M137.5M70.2M1.14M10.1M
Total liabilities237.5M248.4M328.8M724.1M522.4M201.9M88.1M61.6M320.5M
Shareholders' equity765.3M1.15B1.59B2.08B1.43B716.9M423.9M-179.2M-68.9M
Shares outstanding139.5M137.0M134.8M133.2M131.2M127.4M107.6M8.86M127.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-391.8M-446.4M-778.8M1.66B-47.6M-190.9M-129.6M-94.1M-66.4M
Capital spending-4.83M-7.30M-21.6M-68.0M-21.8M-6.55M-8.94M-8.19M-2.74M
Free cash flow-396.6M-453.7M-800.4M1.60B-69.4M-197.5M-138.6M-102.3M-69.1M
Cash from investing310.4M499.4M164.6M-1.19B-140.8M-9.86M-256.2M-60.4M-30.0M
Cash from financing3.79M4.39M7.48M34.8M100.3M529.5M449.2M25.0M271.2M
Dividends paid00
Share buybacks3.22M15.4M327.3M-3.00K14.8M0
Change in cash-77.6M57.4M-606.7M504.6M-88.1M328.7M63.5M-129.6M174.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
424B5 · ProspectusNov 16, 2026Offer documentSEC
8-K · Current reportNov 13, 2026Material contractSEC
424B5 · ProspectusNov 13, 2026Offer documentSEC
424B5 · ProspectusNov 12, 2026Offer documentSEC
S-3ASR · Registration statementNov 12, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 28, 2026Insider tradeSEC
8-K · Current reportOct 28, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 14, 2026FinancingSEC
8-K · Current reportOct 8, 2026Current reportSEC
3 · Initial statement of ownershipOct 6, 2026Insider tradeSEC
8-K · Current reportOct 1, 2026Management or board changeSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
144 · Notice of proposed saleAug 24, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
8-K · Current reportJul 24, 2026Management or board changeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Management or board changeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
144 · Notice of proposed saleApr 30, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
8-K · Current reportApr 10, 2026Management or board changeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
144 · Notice of proposed saleMar 23, 2026Other filingsSEC
8-K · Current reportMar 4, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 3, 2026Big-stake noticeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 26, 2026Material contractSEC
424B5 · ProspectusFeb 26, 2026Offer documentSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
424B5 · ProspectusFeb 24, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 23, 2026Offer documentSEC
10-K · Annual reportFeb 23, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026ResultsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
144 · Notice of proposed saleJan 14, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
8-K · Current reportDec 16, 2025Material contractSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
144 · Notice of proposed saleOct 3, 2025Other filingsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
8-K · Current reportJul 24, 2025Current reportSEC
4 · Change in ownershipJul 17, 2025Insider tradeSEC
144 · Notice of proposed saleJul 17, 2025Other filingsSEC
144 · Notice of proposed saleJul 15, 2025Other filingsSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJun 11, 2025Other filingsSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
144 · Notice of proposed saleJun 2, 2025Other filingsSEC
8-K · Current reportMay 29, 2025Meeting outcomeSEC
8-K · Current reportMay 9, 2025Current reportSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 17, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
144 · Notice of proposed saleApr 3, 2025Other filingsSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 26, 2025Annual reportSEC
144 · Notice of proposed saleFeb 26, 2025Other filingsSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
8-K · Current reportJan 30, 2025Management or board changeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
8-K · Current reportJan 8, 2025Current reportSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC

This page holds 200 of 811 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Vir Biotechnology, Inc.’s releases · as of Nov 13, 2026

Common shares
171,270,773
Fully diluted
171,270,773

Fully diluted

LineSharesAs of
Common shares171,270,773Oct 28, 2026

Share count over time

CountShares
Oct 28, 2026171,270,773

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock22.4M13.1%US$251M+1.77MNov 13, 2026
Vanguard19.6M11.4%US$219M+655KNov 16, 2026
ARCH Venture Management, LLC12.7M7.4%US$142MNo changeNov 16, 2026
Sb Investment Advisers (UK) LTD10.9M6.4%US$122MNo changeNov 17, 2026
GSK plc8.55M5.0%US$95.6MNo changeNov 5, 2026
State Street7.82M4.6%US$87.5M−2.14MNov 12, 2026
Point72 Asset Management, L.P.6.77M4.0%US$75.7M+1.11MNov 16, 2026
Dimensional3.32M1.9%US$37.1M+198KNov 4, 2026
Geode Capital3.02M1.8%US$33.8M−329KNov 6, 2026
Mpm Bioimpact LLC2.81M1.6%US$31.4MNewNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Nuveen2.22M1.3%US$24.8M+239KNov 10, 2026
ADAR1 Capital Management, LLC2.16M1.3%US$24.1M−298KNov 16, 2026
Saturn V Capital Management LP2.04M1.2%US$22.8M+1.27MNov 16, 2026
Pictet Asset Management Holding SA1.9M1.1%US$21.3M−48,558Nov 3, 2026
Morgan Stanley1.77M1.0%US$19.8M−441KNov 13, 2026
Northern Trust1.48M0.87%US$16.6M+50,099Nov 16, 2026
Schwab1.46M0.85%US$16.3M+133KNov 16, 2026
Hudson Bay Capital Management LP1.18M0.69%US$13.1M−189KNov 13, 2026
Two Sigma1.13M0.66%US$12.7M+23,057Nov 16, 2026
Bank of America1.03M0.60%US$11.6M−109KNov 16, 2026
Sio Capital Management, LLC873K0.51%US$9.76M−202KNov 16, 2026
Goldman Sachs847K0.49%US$9.47M−1.52MNov 16, 2026
Savvy Advisors, Inc.838K0.49%US$9.36M−203KNov 12, 2026
JPMorgan834K0.49%US$8.89M+31,745Nov 12, 2026
GordonMD Global Investments LP804K0.47%US$8.98M−550KNov 16, 2026
BNY732K0.43%US$8.18M+37,220Nov 5, 2026
Fidelity640K0.37%US$7.16M−1.68MNov 10, 2026
BNP Paribas640K0.37%US$7.15M−15,430Nov 12, 2026
Candriam S.C.A.616K0.36%US$6.91M−11,011Nov 3, 2026
Clearstead Advisors, LLC608K0.36%US$6.8M−33Nov 6, 2026
Principal607K0.35%US$6.79M+20,127Nov 2, 2026
Superstring Capital Management LP579K0.34%US$6.47M−275KNov 16, 2026
Susquehanna564K0.33%US$6.31M+182KNov 16, 2026
Nordea Investment Management AB546K0.32%US$5.97M−47,599Nov 9, 2026
Invesco539K0.31%US$6.03M+63,416Nov 12, 2026
Alta Partners Management Company, L.P.518K0.30%US$5.79M+8,000Nov 16, 2026
Parkman Healthcare Partners LLC517K0.30%US$5.78M+42,098Nov 16, 2026
Nomura500K0.29%US$5.59MNewNov 16, 2026
UBS445K0.26%US$4.97M−181KNov 16, 2026
Public Sector Pension Investment Board432K0.25%US$4.65M+14,520Nov 10, 2026
American Century409K0.24%US$4.57M+60,126Nov 20, 2026
Citadel403K0.24%US$4.5M−589KNov 16, 2026
Renaissance Technologies396K0.23%US$4.43M−621KNov 12, 2026
Ensign Peak Advisors, Inc390K0.23%US$4.36M−444KNov 12, 2026
Panagora Asset Management Inc371K0.22%US$4.15M−3,356Nov 12, 2026
AQR Capital Management LLC352K0.21%US$3.94M−229KNov 16, 2026
Edgestream Partners, L.P.340K0.20%US$3.8M+206KNov 9, 2026
Hrt Financial LP334K0.20%US$3.73M+26,038Nov 13, 2026
Rhumbline Advisers295K0.17%US$3.3M+9,730Nov 10, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.276K0.16%US$3.08M+79,211Nov 16, 2026

This page holds 50 of 257 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
iShares Core S&P Small-Cap ETF7.32M4.3%US$74.6M+547KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF4.95M2.9%US$50.4M+2.42MJun 30, 2026
Vanguard Total Stock Market Index Fund4.85M2.8%US$49.4M+871KJun 30, 2026
Vanguard Small-Cap Index Fund3.48M2.0%US$35.4M+574KJun 30, 2026
iShares Russell 2000 ETF3.16M1.8%US$32.2M+878KJun 30, 2026
Vanguard Small-Cap Growth Index Fund2M1.2%US$20.3M+373KJun 30, 2026
Vanguard Strategic Equity Fund1.76M1.0%US$18M+467KJun 30, 2026
Vanguard Extended Market Index Fund1.4M0.82%US$14.3M+133KJun 30, 2026
Fidelity Small Cap Index Fund1.34M0.78%US$11.6M+420KJul 31, 2026
iShares Russell 2000 Value ETF1.15M0.67%US$11.7M+350KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF1.11M0.65%US$11.4M+77,651Jun 30, 2026
iShares Biotechnology ETF949K0.55%US$9.67M+245KJun 30, 2026
Nuveen Quant Small Cap Equity Fund892K0.52%US$7.73M−17,660Jul 31, 2026
Vanguard Strategic Small-Cap Equity Fund869K0.51%US$8.85M+396KJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund677K0.40%US$6.9MNo changeJun 30, 2026
U.S. Small Cap Portfolio655K0.38%US$5.67M+2,449Jul 31, 2026
iShares S&P Small-Cap 600 Value ETF621K0.36%US$6.33M−29,144Jun 30, 2026
Fidelity Extended Market Index Fund586K0.34%US$5.59M−1,623May 31, 2026
Schwab U.S. Small-Cap ETF539K0.31%US$5.15M+39,519May 31, 2026
Dimensional U.S. Small Cap ETF536K0.31%US$4.64M+8,129Jul 31, 2026
U.S. Micro Cap Portfolio519K0.30%US$4.5M+3,627Jul 31, 2026
Nomura Healthcare Fund500K0.29%US$5.09MNo changeJun 30, 2026
Vanguard Russell 2000 Index Fund479K0.28%US$4.57M+37,010May 31, 2026
iShares S&P Small-Cap 600 Growth ETF449K0.26%US$4.58M+47,419Jun 30, 2026
JPMorgan Small & Mid Cap Enhanced Equity ETF424K0.25%US$4.32M+16,831Jun 30, 2026
Fidelity Enhanced Small Cap Core ETF414K0.24%US$4.22MNewJun 30, 2026
Vanguard Explorer Fund410K0.24%US$3.55MNo changeJul 31, 2026
Nuveen Quant Small/Mid Cap Equity Fund394K0.23%US$3.42MNo changeJul 31, 2026
Vanguard S&P Small-Cap 600 Index Fund390K0.23%US$3.72M+64,832May 31, 2026
Dimensional U.S. Core Equity 2 ETF373K0.22%US$3.23M+165KJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Value ETF368K0.21%US$3.75M+7,415Jun 30, 2026
BlackRock Advantage Small Cap Core Fund364K0.21%US$3.47M−4,512May 29, 2026
Vanguard Health Care Index Fund351K0.21%US$3.35M+33,665May 31, 2026
College Retirement Equities Fund - Total Global Stock Account349K0.20%US$3.56M+301KJun 30, 2026
Vanguard Market Neutral Fund348K0.20%US$3.55M+97,762Jun 30, 2026
Schwab Small-Cap Index Fund299K0.17%US$2.59M+93,575Jul 31, 2026
iShares Genomics Immunology and Healthcare ETF289K0.17%US$2.51M+122KJul 31, 2026
Avantis U.S. Small Cap Equity ETF283K0.17%US$2.7M+40,701May 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF276K0.16%US$2.82M−243KJun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF271K0.16%US$2.76M+26,659Jun 30, 2026
Master Small Cap Index Series230K0.13%US$2.34M+81,243Jun 30, 2026
Fidelity Total Market Index Fund211K0.12%US$2.01M+26,049May 31, 2026
Invesco RAFI US 1500 Small-Mid ETF209K0.12%US$1.81M+413Jul 31, 2026
JNL Small Cap Index Fund190K0.11%US$1.93M+16,577Jun 30, 2026
U.S. Core Equity 2 Portfolio187K0.11%US$1.62MNo changeJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF172K0.10%US$1.76M+4,080Jun 30, 2026
Fidelity Series Total Market Index Fund172K0.10%US$1.64M+32,597May 31, 2026
Fidelity Small Cap Value Index Fund172K0.10%US$1.75M+56,170Jun 30, 2026
Columbia Small Cap Index Fund168K0.10%US$1.61M+17,911May 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares168K0.10%US$1.46M+23,373Jul 31, 2026

This page holds 50 of 239 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
de Verneuil Vanina
Officer: EVP, General Counsel, Corp Sec
Sale2,407USD 11.10US$26,718Nov 3, 2026
de Verneuil Vanina
Officer: EVP, General Counsel, Corp Sec
Sale1,343USD 11.33US$15,222Nov 2, 2026
Sabatini Brent
Officer: SVP, Chief Accounting Officer
Sale379USD 9.45US$3,582Jun 1, 2026
Napolitano Janet
Director
Sale3,200USD 9.45US$30,240Jun 1, 2026
Sato Vicki L
Director
Sale22,000USD 10.05US$221KMay 1, 2026
De Backer Marianne
Director, Officer: President and CEO
Sale72,559USD 9.16US$665KApr 6, 2026
Sato Vicki L
Director
Sale22,000USD 9.07US$200KApr 1, 2026

Big stakes

HolderStakeSharesDate
BlackRock, Inc.12.40%20.9MSep 30, 2026
Robert Nelsen7.30%12.5MNov 4, 2026
Vanguard Portfolio Management LLC6.85%11.6MJun 30, 2026
Sb Investment Advisers (UK) LTD6.50%10.9MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Nelsen
Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past)
Director · Oct 10, 2019 – May 30, 2024 · Past
Kristina Burow
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past)
Director · Oct 10, 2019 – May 21, 2020 · Past
Robert J Perez
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Larimar Therapeutics, Inc. (Director · Sep 24, 2015 – Jun 26, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past)
Director · Oct 10, 2019 – May 22, 2023 · Past
Vicki Sato
Other companies: Allogene Therapeutics, Inc. (Director · Since at least Jul 30, 2021); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jan 2, 2025 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 11, 2019 · Past); BorgWarner Inc. (Director · Feb 12, 2014 – Apr 29, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2010 · Past); Bristol-Myers Squibb Company (Director · Jul 11, 2006 – Feb 1, 2021 · Past); Revvity, Inc. (Director · May 2, 2006 – Feb 9, 2017 · Past)
Director · Since at least Oct 10, 2019
Saira Ramasastry
Other companies: Sensei Biotherapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jun 15, 2026); Mirum Pharmaceuticals, Inc. (Director · Since at least Jun 2, 2022); Day One Biopharmaceuticals Inc (Director · Since at least May 26, 2021); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Repros Therapeutics (Director · Mar 25, 2013 – Jan 29, 2018 · Past); Filana Therapeutics, Inc. (Director · Feb 11, 2013 – Dec 13, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 21, 2012 – Feb 25, 2022 · Past)
Director · Since at least Oct 10, 2019
Dipchand Nishar
Other companies: Seer, Inc. (Director · Since at least Feb 13, 2021); Senti Biosciences Holdings, Inc. (Director · May 25, 2021 – May 25, 2021 · Past); Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jul 15, 2020 · Past); Guardant Health, Inc. (Director · Oct 3, 2018 – May 18, 2020 · Past); TripAdvisor, Inc. (Director · Sep 5, 2013 – Jun 21, 2019 · Past); LinkedIn Corp (SVP, Products, User Experience · May 18, 2011 – Sep 2, 2014 · Past)
Director · Oct 10, 2019 – May 21, 2021 · Past
Jeffrey S. Hatfield
Other companies: Larimar Therapeutics, Inc. (Chief Executive Officer, Director · Oct 9, 2017 – Jan 22, 2019 · Past); Viridian Therapeutics, Inc. (Director · Aug 10, 2017 – Feb 4, 2021 · Past); aTyr Pharma, Inc. (Director · Apr 3, 2017 – May 6, 2020 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 1, 2016 – Jan 19, 2018 · Past); Vitae Pharmaceuticals Inc (Chief Executive Officer, Director · Sep 24, 2014 – Oct 24, 2016 · Past); Ambit Biosciences Corp (Director · Jun 2, 2014 – Nov 10, 2014 · Past)
Chair of the Board · Since at least Dec 9, 2020
Michael E Kamarck
Other companies: Passage Bio, Inc. (Director · Jul 2, 2022 – May 25, 2023 · Past); Vaxcyte, Inc. (Director · Oct 27, 2021 – Jun 13, 2023 · Past); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past); Unilife Corp (Director · Jul 28, 2016 – Jul 28, 2016 · Past); Omni Bio Pharmaceutical Inc (Director · Jan 31, 2013 – Jan 31, 2013 · Past)
Chief Technology Officer · Oct 10, 2019 – Oct 10, 2019 · Past
Timothy P. Coughlin
Other companies: ADC Therapeutics SA (Director · Since at least Jun 3, 2025); aTyr Pharma, Inc. (Chairman · Since at least Apr 7, 2017); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past)
Director · Since Jun 9, 2026
George Scangos
Other companies: Voyager Therapeutics, Inc. (Director · Since at least May 9, 2023); Agilent Technologies, Inc. (Director · Since at least Mar 16, 2017); Exelixis, Inc. (Director · May 26, 2016 – May 18, 2020 · Past); Biogen Inc. (Chief Executive Officer, Director · Apr 1, 2016 – Jul 21, 2016 · Past)
Director · Oct 10, 2019 – Feb 24, 2025 · Past
All 43 people
PersonSeat
Charles Elliott Sigal
Other companies: Alnylam Pharmaceuticals, Inc. (Director · Since at least Aug 22, 2022); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 3, 2023 · Past)
Director · Since at least Jul 10, 2020
Mark Eisner
Other companies: Jade Biosciences, Inc. (Director · Since at least Jun 25, 2026); Zura Bio Limited (Director · Since at least Feb 21, 2026); Kyntra Bio, Inc. (EVP, Chief Medical Officer · Dec 1, 2020 – Sep 6, 2023 · Past)
EVP and Chief Medical Officer · Since at least Jun 3, 2024
Norbert Bischofberger
Other companies: Kronos Bio Inc (Director · Since at least Oct 8, 2020); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Gilead Sciences, Inc. (EVP, R&D and CSO · Jan 25, 2006 – Feb 15, 2018 · Past)
Director · Since at least May 29, 2024
Phillip A Sharp
Other companies: Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 1, 2022 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2006 – Jan 23, 2025 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jun 3, 2009 · Past)
Director · Oct 10, 2019 – May 22, 2023 · Past
Sung Lee
Other companies: Tango Therapeutics, Inc. (Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026); Cytokinetics, Incorporated (EVP, Chief Financial Officer · Since at least Apr 26, 2024); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past)
EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past
Janet Napolitano
Other companies: Fortinet, Inc. (Director · Since at least Nov 7, 2024); Zoom Communications, Inc. (Director · Since at least Nov 2, 2020)
Director · Since at least Aug 28, 2020
Jason V. O'Byrne
Other companies: Olema Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Aug 11, 2026); Caribou Biosciences, Inc. (Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past)
EVP & Chief Financial Officer · Since at least Oct 2, 2024
Marianne De Backer
Other companies: Kronos Bio Inc (Director · Jan 25, 2021 – Jun 22, 2023 · Past); Arrowhead Pharmaceuticals, Inc. (Director · Dec 12, 2019 – Jan 10, 2023 · Past)
PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR · Since at least Apr 3, 2023
Ramy Farid
Other companies: Schrodinger, Inc. (President and CEO, Board Member · Since at least Feb 5, 2020); Structure Therapeutics, Inc. (Director · Feb 2, 2023 – Feb 7, 2023 · Past)
Director · Since at least May 29, 2024
Robert More
Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Sep 14, 2021); Glaukos Corporation (Director · Jun 24, 2015 – Jun 30, 2015 · Past)
Director · Since at least Oct 10, 2019
Aziz Sawaf
Other companies: Theravance Biopharma, Inc. (SVP & CHIEF FINANCIAL OFFICER · Since at least Jan 1, 2023)
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICer · Since at least Oct 1, 2026
Elliott Sigal
Other companies: Alnylam Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026)
Director · Since at least Nov 5, 2026
Howard Horn
Other companies: Ultragenyx Pharmaceutical Inc. (Chief Financial Officer · Since at least Oct 9, 2023)
CFO · Oct 10, 2019 – Feb 23, 2023 · Past
Johanna Friedl-Naderer
Other companies: Dyne Therapeutics, Inc. (Chief Commercial Officer · Since at least Sep 3, 2024)
EVP & Chief Operating Officer · Mar 2, 2022 – Mar 3, 2023 · Past
Ann M HanlyEVP & Chief Technology Officer · Mar 29, 2021 – Feb 24, 2025 · Past
Arran AttridgeSenior Vice President, Corporate Communications · Mar 13, 2025 – Nov 4, 2026 · Past
Brent SabatiniInterim Principal Financial Officer · Since at least Oct 1, 2024
Carolyn WangSENIOR VICE PRESIDENT CORPORATE COMMUNICATIONS · Since at least Nov 5, 2026
David LiuEXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER · Since at least Oct 7, 2026
Herbert VirginEVP, Research & CSO · Oct 10, 2019 – Aug 9, 2022 · Past
InvestorsNeera RavindranMDHead of Investor Relations & Strategic · Since at least Feb 23, 2026
Jay ParrishChief Business Officer · Oct 10, 2019 – Apr 1, 2021 · Past
Jeff CalcagnoExecutive Vice President and Chief Business Officer · Since at least Nov 4, 2026
Jennifer Eileen TowneExecutive Vice President and Chief Scientific Officer · Since at least Nov 5, 2026
Kiki PatelPharmDHead of Investor Relations · Since at least Nov 2, 2026
Klaus FruehDirector · Oct 10, 2019 – Oct 16, 2019 · Past
Maninder HoraEXECUTIVE VICE PRESIDENT AND CHIEF TECHNICAL OPERATIONS OFFICER · Since at least Feb 26, 2025
Phillip PangEVP & Chief Medical Officer · Oct 10, 2019 – Feb 22, 2024 · Past
Richard LepkeSenior Director, Investor Relations · Oct 9, 2025 – Nov 4, 2026 · Past
Steven J RiceChief Administrative Officer · Jul 30, 2020 – Jun 1, 2023 · Past
Suzanne TopalianDirector · Since at least Oct 27, 2026
Toby MedarisEXECUTIVE VICE PRESIDENT AND CHIEF HUMAN RESOURCES OFFICER · Since at least Nov 4, 2026
Vanina de VerneuilExecutive Vice President General Counsel and Corporate Secretary · Since at least Oct 1, 2024

Open People

Log in to ask 6ix AI your own questions about Vir Biotechnology, Inc.